ABX 4233
Alternative Names: ABX-4233Latest Information Update: 04 Jul 2025
At a glance
- Originator NGM Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Lymphotoxin beta receptor agonists; V-set domain-containing T-cell activation inhibitor 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Apr 2025 Preclinical trials in Solid tumours in USA (unspecified route)
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 NGM Biopharmaceuticals plans a clinical trial for Solid tumours in